KR20040029429A - 이속사졸로피리디논 및 파킨슨병의 치료에 있어서 그의용도 - Google Patents

이속사졸로피리디논 및 파킨슨병의 치료에 있어서 그의용도 Download PDF

Info

Publication number
KR20040029429A
KR20040029429A KR10-2004-7002124A KR20047002124A KR20040029429A KR 20040029429 A KR20040029429 A KR 20040029429A KR 20047002124 A KR20047002124 A KR 20047002124A KR 20040029429 A KR20040029429 A KR 20040029429A
Authority
KR
South Korea
Prior art keywords
alkyl
alkylamino
alkoxy
phenyl
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR10-2004-7002124A
Other languages
English (en)
Korean (ko)
Inventor
자무엘 힌터만
바스티안 헹에러
울리케 폰 크로직크
Original Assignee
노파르티스 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 노파르티스 아게 filed Critical 노파르티스 아게
Publication of KR20040029429A publication Critical patent/KR20040029429A/ko
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
KR10-2004-7002124A 2001-08-15 2002-08-14 이속사졸로피리디논 및 파킨슨병의 치료에 있어서 그의용도 Ceased KR20040029429A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0119911.6A GB0119911D0 (en) 2001-08-15 2001-08-15 Organic Compounds
GB0119911.6 2001-08-15
PCT/EP2002/009134 WO2003015780A2 (en) 2001-08-15 2002-08-14 Isoxazolopyridinones and use thereof in the treatment of parkinson's disease

Publications (1)

Publication Number Publication Date
KR20040029429A true KR20040029429A (ko) 2004-04-06

Family

ID=9920454

Family Applications (1)

Application Number Title Priority Date Filing Date
KR10-2004-7002124A Ceased KR20040029429A (ko) 2001-08-15 2002-08-14 이속사졸로피리디논 및 파킨슨병의 치료에 있어서 그의용도

Country Status (24)

Country Link
US (1) US7087756B2 (cg-RX-API-DMAC7.html)
EP (1) EP1418912B1 (cg-RX-API-DMAC7.html)
JP (1) JP2005501847A (cg-RX-API-DMAC7.html)
KR (1) KR20040029429A (cg-RX-API-DMAC7.html)
CN (1) CN100384418C (cg-RX-API-DMAC7.html)
AR (1) AR036351A1 (cg-RX-API-DMAC7.html)
AT (1) ATE355059T1 (cg-RX-API-DMAC7.html)
BR (1) BR0211903A (cg-RX-API-DMAC7.html)
CA (1) CA2454762A1 (cg-RX-API-DMAC7.html)
CO (1) CO5560566A2 (cg-RX-API-DMAC7.html)
DE (1) DE60218484T2 (cg-RX-API-DMAC7.html)
EC (1) ECSP044971A (cg-RX-API-DMAC7.html)
ES (1) ES2282467T3 (cg-RX-API-DMAC7.html)
GB (1) GB0119911D0 (cg-RX-API-DMAC7.html)
HU (1) HUP0401325A3 (cg-RX-API-DMAC7.html)
IL (1) IL160018A0 (cg-RX-API-DMAC7.html)
MX (1) MXPA04001419A (cg-RX-API-DMAC7.html)
NO (1) NO20040659D0 (cg-RX-API-DMAC7.html)
PE (1) PE20030356A1 (cg-RX-API-DMAC7.html)
PL (1) PL366848A1 (cg-RX-API-DMAC7.html)
PT (1) PT1418912E (cg-RX-API-DMAC7.html)
RU (1) RU2004107847A (cg-RX-API-DMAC7.html)
WO (1) WO2003015780A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA200400525B (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20170033630A (ko) 2015-09-17 2017-03-27 (주)다올 도로용 경계블럭

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002102807A1 (en) * 2001-06-14 2002-12-27 Banyu Pharmaceutical Co., Ltd. Novel isoxazolopyridone derivatives and use thereof
CA2564429A1 (en) * 2004-05-14 2005-12-01 Irm Llc Compounds and compositions as ppar modulators
WO2007098047A2 (en) * 2006-02-16 2007-08-30 The Mclean Hospital Corporation Methods and compositions for the treatment of parkinson's disease
EP2051977A2 (en) 2006-07-20 2009-04-29 Amgen Inc. SUBSTITUTED AZOLE AROMATIC HETEROCYCLES AS INHIBITORS OF LLbeta-HSD-1
FR2906250B1 (fr) * 2006-09-22 2008-10-31 Sanofi Aventis Sa Derives de 2-aryl-6phenyl-imidazo(1,2-a) pyridines, leur preparation et leur application en therapeutique
FR2933609B1 (fr) * 2008-07-10 2010-08-27 Fournier Lab Sa Utilisation de derives d'indole comme activateurs de nurr-1, pour le traitement de la maladie de parkinson.
US8173670B2 (en) * 2009-01-13 2012-05-08 Van Andel Research Institute Methods of using substituted isoxazolo pyridinones as dissociated glucocorticoids
FR2950053B1 (fr) 2009-09-11 2014-08-01 Fournier Lab Sa Utilisation de derives d'indole benzoique comme activateurs de nurr-1, pour le traitement de la maladie de parkinson
FR2955110A1 (fr) 2010-01-08 2011-07-15 Fournier Lab Sa Nouveaux derives de type pyrrolopyridine benzoique
DE102011085038A1 (de) 2011-10-21 2013-04-25 Tesa Se Verfahren zur Kapselung einer elektronischen Anordnung
HK1222565A1 (zh) 2013-09-25 2017-07-07 范安德尔研究所 高效糖皮質激素
US10954265B2 (en) 2016-10-14 2021-03-23 Van Andel Research Institute Structures and mechanism for the design of highly potent glucocorticoids

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE7602542L (sv) 1975-03-14 1976-09-15 Sandoz Ag 3-(alfa-iminobensyl)-4-hydroxi-2(lh)-pyridoner
US4064251A (en) * 1976-06-25 1977-12-20 Sandoz, Inc. Substituted hydroxy pyridones
US4049813A (en) 1976-07-15 1977-09-20 Sandoz, Inc. Substituted isoxazolo pyridinones
DE2801190A1 (de) * 1977-01-19 1978-07-20 Sandoz Ag 3-(alpha-iminobenzyl)-4-hydroxy-2(1h)- pyridon-derivat
US4238616A (en) 1977-01-19 1980-12-09 Sandoz, Inc. 3-(Substituted)phenyl-5-(β-hydroxyphenethyl)-N-(alkyl)-isoxazole-4-carboxamides
US4113727A (en) * 1977-04-26 1978-09-12 Sandoz, Inc. Process for the preparation of substituted isoxazolo[4,5-c]pyridin-4-(5H)-ones
WO2002102807A1 (en) * 2001-06-14 2002-12-27 Banyu Pharmaceutical Co., Ltd. Novel isoxazolopyridone derivatives and use thereof

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20170033630A (ko) 2015-09-17 2017-03-27 (주)다올 도로용 경계블럭

Also Published As

Publication number Publication date
CO5560566A2 (es) 2005-09-30
NO20040659L (no) 2004-02-13
BR0211903A (pt) 2004-09-21
HUP0401325A2 (hu) 2004-10-28
MXPA04001419A (es) 2004-05-27
CN100384418C (zh) 2008-04-30
ECSP044971A (es) 2004-03-23
US7087756B2 (en) 2006-08-08
DE60218484D1 (de) 2007-04-12
NO20040659D0 (no) 2004-02-13
PT1418912E (pt) 2007-05-31
PL366848A1 (en) 2005-02-07
CN1635889A (zh) 2005-07-06
JP2005501847A (ja) 2005-01-20
WO2003015780A8 (en) 2004-05-21
DE60218484T2 (de) 2007-11-15
ES2282467T3 (es) 2007-10-16
EP1418912B1 (en) 2007-02-28
CA2454762A1 (en) 2003-02-27
PE20030356A1 (es) 2003-05-14
ZA200400525B (en) 2005-04-01
US20040248893A1 (en) 2004-12-09
IL160018A0 (en) 2004-06-20
WO2003015780A3 (en) 2003-11-13
RU2004107847A (ru) 2005-05-10
HUP0401325A3 (en) 2005-09-28
ATE355059T1 (de) 2006-03-15
EP1418912A2 (en) 2004-05-19
GB0119911D0 (en) 2001-10-10
WO2003015780A2 (en) 2003-02-27
AR036351A1 (es) 2004-09-01

Similar Documents

Publication Publication Date Title
CN105209443B (zh) 吲哚胺2,3-双加氧酶(ido)抑制剂
JP6051210B2 (ja) 有機化合物
CN106573899B (zh) 用于治疗炎性、代谢性、肿瘤性和自身免疫性疾病的任选稠合的、经杂环基取代的嘧啶衍生物
TW201206944A (en) Morpholine compounds
CN101006065B (zh) 抑制bcl蛋白与结合伴侣的相互作用的化合物和方法
HK1208218A1 (en) Organic compounds
CN105008352A (zh) 用作溴区结构域抑制剂的咔唑化合物
TW201542567A (zh) 用於增進先天性免疫反應之化合物及方法
US7087756B2 (en) Isoxazolopyridinones
JP2004524317A (ja) アンドロゲン受容体モジュレーター化合物としての三環式キノリノンおよび三環式キノリン
CN109863151A (zh) 用于治疗正粘病毒感染的稠合三环哒嗪酮化合物
TW202035412A (zh) 雜芳基二氫嘧啶衍生物和治療b型肝炎感染之方法
TW200804378A (en) Organic compounds
CN107922353A (zh) Ido抑制剂
CN102245600A (zh) 吡咯烷酮黑色素浓集激素受体-1拮抗剂
TW201016698A (en) Antiviral compounds
CN114341135A (zh) 雌激素相关受体α(ERRα)调节剂
EP3621620A1 (en) Substituted heterocyclic compounds as allosteric modulators of group ii metabotropic glutamate receptors
AU2002336977A1 (en) Isoxazolopyridinones and use thereof in the treatment of Parkinson's disease
BRPI0620647A2 (pt) derivados de furopirimidina ciclicamente substituìdos, processo para a preparação e uso dos mesmos e medicamento
WO2005016255A2 (en) Substituted tetrahydroquinolines, phenylacetic acids and benzoic acids as hepatocyte nuclear factor 4 (hnf-4 ) modulator compounds
CN114656480B (zh) 噻吩并嘧啶类化合物、异构体或盐及其制备方法和用途
CN114671876B (zh) 新型茶碱类化合物、异构体或盐及其制备方法和用途
WO2005017185A2 (en) HEPATOCYTE NUCLEAR FACTOR 4α MODULATOR COMPOUNDS
CN117534617A (zh) 一类2-氨基咪唑啉类化合物、其用途和含该化合物的药物组合物

Legal Events

Date Code Title Description
A201 Request for examination
PA0105 International application

Patent event date: 20040212

Patent event code: PA01051R01D

Comment text: International Patent Application

PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20040212

Comment text: Request for Examination of Application

PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20050926

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20060302

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20050926

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I